Log in

NASDAQ:ANABAnaptysBio Stock Price, Forecast & News

$15.26
+1.16 (+8.23 %)
(As of 04/7/2020 08:00 AM ET)
Add
Compare
Today's Range
$14.59
Now: $15.26
$15.28
50-Day Range
$12.82
MA: $15.10
$18.69
52-Week Range
$10.00
Now: $15.26
$81.46
Volume691,300 shs
Average Volume679,650 shs
Market Capitalization$415.99 million
P/E RatioN/A
Dividend YieldN/A
Beta0.88
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases. It is also developing immuno-oncology products, including TSR-042: anti-PD-1, TSR-022: anti-TIM-3, TSR-033: anti-LAG-3, and TSR-075: anti-PD-1/LAG-3 bispecific; and CC-90006: anti-PD-1 agonist for psoriasis, as well as other products for inflammation. AnaptysBio, Inc. has an immuno-oncology partnership with TESARO, Inc. and TESARO Development, Ltd., including an anti-PD-1 antagonist antibody (TSR-042), an anti-TIM-3 antagonist antibody (TSR-022), and an anti-LAG-3 antagonist antibody (TSR-033); and an inflammation partnership with Celgene Corporation, including an anti-PD-1 checkpoint agonist antibody (CC-90006) in clinical development. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is headquartered in San Diego, California.
Read More
AnaptysBio logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.1Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.30 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ANAB
CUSIPN/A
Phone858-362-6295

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8 million
Book Value$14.93 per share

Profitability

Net Income$-97,340,000.00

Miscellaneous

Employees78
Market Cap$415.99 million
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive ANAB News and Ratings via Email

Sign-up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter.


AnaptysBio (NASDAQ:ANAB) Frequently Asked Questions

How has AnaptysBio's stock been impacted by COVID-19 (Coronavirus)?

AnaptysBio's stock was trading at $15.23 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ANAB stock has increased by 0.2% and is now trading at $15.26. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of AnaptysBio?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last year. There are currently 1 sell rating, 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for AnaptysBio.

When is AnaptysBio's next earnings date?

AnaptysBio is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for AnaptysBio.

How were AnaptysBio's earnings last quarter?

AnaptysBio Inc (NASDAQ:ANAB) posted its quarterly earnings data on Monday, March, 2nd. The biotechnology company reported ($0.75) EPS for the quarter, topping the consensus estimate of ($1.20) by $0.45. The biotechnology company had revenue of $3 million for the quarter, compared to the consensus estimate of $3 million. View AnaptysBio's earnings history.

What price target have analysts set for ANAB?

9 Wall Street analysts have issued 1-year price objectives for AnaptysBio's shares. Their forecasts range from $12.00 to $140.00. On average, they expect AnaptysBio's stock price to reach $53.57 in the next twelve months. This suggests a possible upside of 251.1% from the stock's current price. View analysts' price targets for AnaptysBio.

Has AnaptysBio been receiving favorable news coverage?

Media stories about ANAB stock have been trending very negative recently, according to InfoTrie Sentiment. The research group identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. AnaptysBio earned a daily sentiment score of -3.3 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutAnaptysBio.

Are investors shorting AnaptysBio?

AnaptysBio saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 5,964,100 shares, an increase of 5.7% from the February 27th total of 5,640,000 shares. Based on an average daily volume of 692,000 shares, the short-interest ratio is presently 8.6 days. Approximately 25.1% of the shares of the stock are short sold. View AnaptysBio's Current Options Chain.

Who are some of AnaptysBio's key competitors?

What other stocks do shareholders of AnaptysBio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AnaptysBio investors own include Crispr Therapeutics (CRSP), Editas Medicine (EDIT), ImmunoGen (IMGN), Amarin (AMRN), Baozun (BZUN), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Alibaba Group (BABA), Anavex Life Sciences (AVXL) and Baidu (BIDU).

Who are AnaptysBio's key executives?

AnaptysBio's management team includes the following people:
  • Mr. Hamza Suria, Pres, CEO & Director (Age 43)
  • Mr. Dominic G. Piscitelli M.B.A., CPA, Chief Financial Officer (Age 44)
  • Prof. Marco Londei, Chief Medical Officer (Age 62)
  • Mr. Eric J. Loumeau, Gen. Counsel (Age 56)
  • Dr. Hemant Kumar, Sr. VP of Manufacturing

When did AnaptysBio IPO?

(ANAB) raised $60 million in an initial public offering on Thursday, January 26th 2017. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Credit Suisse and Stifel served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is AnaptysBio's stock symbol?

AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."

How do I buy shares of AnaptysBio?

Shares of ANAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AnaptysBio's stock price today?

One share of ANAB stock can currently be purchased for approximately $15.26.

How big of a company is AnaptysBio?

AnaptysBio has a market capitalization of $415.99 million and generates $8 million in revenue each year. The biotechnology company earns $-97,340,000.00 in net income (profit) each year or ($3.60) on an earnings per share basis. AnaptysBio employs 78 workers across the globe. View additional information about AnaptysBio.

What is AnaptysBio's official website?

The official website for AnaptysBio is http://www.anaptysbio.com/.

How can I contact AnaptysBio?

AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-362-6295 or via email at [email protected]

This page was last updated on 4/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel